Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + Sintilimab + AG in Pancreatic Cancer
NCT05481476Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in pancreatic cancer (PC), sponsored by Sun Yat-sen University. Started Dec 2022; status: active, not recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05481476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481476.